Emory Center for Psychedelics and Spirituality

BrainFutures

Hendrick, P. S. Back to the future: A return to psychedelic treatment models for addiction. Journal of Psychopharmacology, doi: 10.1177/0269881114550935 (2014).

David Steindl-Rast, O.S.B., Mount Savior Monastery (2000)

Griffiths, R.R., Richards, W.A., McCann, U., & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187, 268-283, doi: 10.1007/s00213-006-0457-5 (2006).

Halpern, J.H., Sherwood, A.R., Passie, T., Blackwell, K.C., & Ruttenber, A.J. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit 14, SR15-22 (2008).

Johnson, M., Richards, W., & Griffiths, R. Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology 22, 603-620, doi: 10.1177/0269881108093587 (2008).

Krupitsky, E.M., Burakov, A.M., Dunaevsky, I.V., Romanova, T.N., Slavina, T.Y., & Grinenko, A.Y. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. Journal of Psychoactive Drugs 39, 13-19 (2007).

Kurland, A.A., Grof, S., Pahnke, W.N., Goodman, L.E. Psychedelic drug assisted psychotherapy in patients with terminal cancer. Psychopharmacological Agents--Dying Patients, Bereaved. Columbia University Press, 86-133 (1973).

Ludwig, A., Levine, J., Stark, L., & Lazar, R. A clinical study of LSD treatment in alcoholism. Am J Psychiatry 126, 59-69 (1969).

Mitchell, J.M., Bogenschutz, M., Lilienstein, A., et al. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine 27, 1025–1033, doi: 10.1038/s41591-021-01336-3 (2021).